Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FNBAC
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,338
Award facts
- Contract value 100% obligated
- $19,338.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $19,338.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors with an ultimate completion date of September 22, 2025. This non-set-aside award represents a competitive procurement of a brand-name biologic medication used to treat atopic dermatitis, eczema, asthma, and chronic rhinosinusitis with nasal polyps. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal healthcare systems, and this delivery order falls under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026.
This delivery order reflects routine pharmaceutical procurement within DLA's broader medical supply chain operations supporting military and veteran healthcare systems. AmerisourceBergen's extensive portfolio of federal contract awards demonstrates its established capability to supply specialty medications and medical commodities across multiple therapeutic domains. The firm fixed-price delivery order structure and competitive award indicate that AmerisourceBergen successfully met federal procurement requirements for this specific pharmaceutical need, consistent with its role as a critical vendor within the DLA Pharmaceutical Prime Vendor program serving the Defense Health Agency and other federal healthcare customers.
Quick answers
Who was awarded contract SPE2DB25FNBAC?
SPE2DB25FNBAC was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 19, 2025.
How much is contract SPE2DB25FNBAC worth?
The government has obligated $19,338 on SPE2DB25FNBAC.
Is contract SPE2DB25FNBAC an order under another contract?
Yes. SPE2DB25FNBAC is a delivery order under SPE2DB20D2104, an indefinite delivery contract.
Was contract SPE2DB25FNBAC competed?
The extent of competition for SPE2DB25FNBAC was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award